Zrivada en es it fr

Zrivada Brand names, Zrivada Analogs

Zrivada Brand Names Mixture

  • No information avaliable

Zrivada Chemical_Formula


Zrivada RX_link


Zrivada fda sheet

Zrivada FDA

Zrivada msds (material safety sheet)

Zrivada Synthesis Reference

No information avaliable

Zrivada Molecular Weight

704.856 g/mol

Zrivada Melting Point

No information avaliable

Zrivada H2O Solubility

Free base slightly soluble (4-5 mg/mL)

Zrivada State


Zrivada LogP


Zrivada Dosage Forms

Capsule (100 mg, 150 mg, or 200 mg)

Zrivada Indication

For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection.

Zrivada Pharmacology

Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). It is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Zrivada Absorption

Atazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability

Zrivada side effects and Toxicity

No information avaliable

Zrivada Patient Information

Zrivada Organisms Affected

Human immunodeficiency virus